Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia

BACKGROUND: Patients with relapsed/refractory (R/R) Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL) have a poor prognosis and limited treatment options. METHODS: The efficacy of inotuzumab ozogamicin (InO), a humanized anti‐CD22 monoclonal antibody conjugated to the cytotox...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Stock, Wendy, Martinelli, Giovanni, Stelljes, Matthias, DeAngelo, Daniel J., Gökbuget, Nicola, Advani, Anjali S., O’Brien, Susan, Liedtke, Michaela, Merchant, Akil A., Cassaday, Ryan D., Wang, Tao, Zhang, Hui, Vandendries, Erik, Jabbour, Elias, Marks, David I., Kantarjian, Hagop M.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983935/
https://ncbi.nlm.nih.gov/pubmed/33231879
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.33321
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars